Diabetic Retinopathy Assessed by Ultra-wide

NCT03157206 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 49

Last updated 2017-06-08

No results posted yet for this study

Summary

Patients with diabetic macular edema treated with aflibercept injections for visual impairment will be observed in standard care during 12 months. They will undergo visual assessments by Ultrawide Field angiography at baseline and at 12 months

Conditions

Sponsors & Collaborators

  • Association Pour La Recherche En Vision Du Service D'Ophtalmologie De L'Hôpital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-19
Primary Completion
2019-07-18
Completion
2020-09-18

Countries

  • France

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03157206 on ClinicalTrials.gov